Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)

February 13, 2025 8:55 PM EST Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $140.00 price target on Ultragenyx Pharma (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login